全球人工授精市场2017-2027：行业规模、份额、趋势、机会和技术、组件、供应商、最终用户、公司和地区预测

在 2027 年之前的预测期内，全球人工授精市场预计将呈现显着增长。

不断上升的不孕率和有利的政府举措正在推动市场的增长。此外，预计到 2027 年，持续的技术进步和人工授精意识的增强也将对市场增长产生重大影响。

在本报告中，我们调查了全球人工授精市场、市场概况、市场规模和市场份额趋势和预测，按每个细分市场/地区/主要国家进行了详细分析，并对市场的各种影响因素进行了分析。竞争环境、主要公司概况等。

内容

第 1 章产品概述

第二章研究方法论

第 3 章执行摘要

第 4 章 COVID-19 对全球人工授精市场的影响

第五章VOC（客户之声）

第六章全球人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 通过技术（宫内、宫颈内、阴道内、输卵管内）
  • 按组件（授精套件、家庭受孕设备、其他）
  • 按供应商 (AIH/AID)
  • 按最终用户（医院、生育诊所和中心等）
  • 按公司
  • 按地区
• 产品市场地图

第七章北美人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 按技术
  • 按组件
  • 按供应来源
  • 最终用户
  • 按国家
• 国家分析

第八章：欧洲人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 按技术
  • 按组件
  • 按供应来源
  • 最终用户
  • 按国家
• 国家分析

第9章亚太人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 按技术
  • 按组件
  • 按供应来源
  • 最终用户
  • 按国家
• 国家分析

第10章南美人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 按技术
  • 按组件
  • 按供应来源
  • 最终用户
  • 按国家
• 国家分析

第 11 章中东和非洲人工授精市场展望

• 市场规模和预测
• 市场份额/预测
  • 按技术
  • 按组件
  • 按供应来源
  • 最终用户
  • 按国家
• 国家分析

第 12 章市场动态

• 司机
• 任务

第13章市场趋势与市场发展

第14章竞争格局

• Rocket Medical plc
• Kitazato Corporation
• Vitrolife AB
• Genea Limited
• Rinovum Women's Health, LLC
• Pride Angel Limited
• FUJIFILM Irvine Scientific, Inc.
• Conceivex, Inc.
• Surelife Pte Ltd.
• Biogenics Inc.

第15章 策略建议

The global artificial insemination market is grow at impressive rate through 2027. The Medical practitioners practice artificial insemination fertilization method for placing the sperm directly into a female's cervix, fallopian tube, or uterus. These practices are performed on couples or patient-facing fertility issues to achieve pregnancy, as the chances are very high. Due to technological advancement, each step is observed very minutely to reduce the chances of any complication that make this process safer for both mother and baby. According to the UN reports in 2017, the total fertility rate is predicted to decline up to 2.39 (children per woman) between the years 2020 and 2030.

Increasing infertility rate and favorable government initiatives are driving the growth of the market. Furthermore, ongoing technical advancements and increasing awareness about artificial insemination are other factors that are expected to significantly influence the growth of the market through 2027.

Increasing Infertility Rate is Driving the Market Growth

People are facing different problems and issues due to changes in the daily lifestyle of people in the modern world. It includes the food, sleep cycle, physical activities, and mental health, like stress, anxiety, and other problems. The increasing pervasiveness of the problem, consumption of unclean foods, alcohol, tobacco, and diseases like endometriosis, sterilization, cervical mucus problem, and other factors responsible for infertility led to the growth of the Artificial Insemination Market. Family planning and marriages after the 30s increased medical treatment demand for curing infertility. According to the WHO, almost 48 million couples and 186 million individuals have infertility worldwide, accounts 15% of the population. Thus, the above data indicate a positive increase in the market growth of the artificial insemination market in the upcoming year. Many insurance companies are accepting artificial insemination under medical coverage. These initiatives are helping the patient to fight infertility and driving the growth in Artificial Insemination Market.

Peoples are the main asset for any country that can participate and support countries in economic development and growth. Hence, governments are launching various schemes to make their medical infrastructure better and broadly available to meet global benchmarks. The government and international identities make policies and induct new institutions to enhance their medical connectivity, such Assisted Reproductive Technology (ART) Regulation Bill, Nation Public Action Plan, National Family Policy, and other initiatives. As per UNSC, 84% of the country supports the policy that directly and indirectly affects the country's infertility. These policies led to increasing demand for artificial insemination in the market. All the factors mentioned above are expected to drive the growth of the artificial insemination market.

Cost Related with Artificial Insemination is Hindering the Growth

The medical cost for the artificial insemination technique in the USA is between 400 dollars to 4000 dollars approximately. The cost associated with the treatment process is still very costly for many peoples. As it is a medical process, there is a chance of negative pregnancy results after the process is completed. In these cases, patients' losses all their money without any satisfactory result. Many financial institutions are providing medical insurance coverage for artificial insemination. Apart from these supply chain disturbances, the lack of unskilled labor is another factor responsible for restraining market growth.

Increase in Deliberate Collaboration and Product Launch

Growth in market share of the artificial insemination market is propelling the launch of new products and strategic partnerships between two organizations. These scenarios will help both organizations to use their competencies and increase the revenue share. As the market is growing, market players are investing aggressively, leading to technological advancements, and extending their niche market.

In 2021, Vitrolife AB acquired Igenomix S.L to help them extend their product line in existing and target new market segments using their strong competencies.

In 2020, Genea Limited collaborated with Hamilton's throne partner. This step allowed both companies to make good relationships with the customer in USA and Canada and grow the Genea Biomedx operations and customer support.

Market Segmentation

The global artificial insemination market is segmented based on technique, component, source, and end-user. Based on technique, market is divided into intrauterine, intracervical, intravaginal, and intratubal. Based on component type, market is divided into Insemination Kits, Home Conception Devices, and Others. Based on source type, market is split into AIH-Husband, and AID-Donor. Based on end user, market is divided into hospitals, fertility clinics & centers, and others, by company.

Market Players

Rocket Medical plc, Kitazato Corporation, Vitrolife AB, Genea Limited, Rinovum Women's Health, LLC, Pride Angel Limited, FUJIFILM Irvine Scientific, Inc., Conceivex, Inc., Surelife Pte Ltd., Biogenics Incare the major market player in Artificial Insemination Market.

Report Scope:

In this report, global Artificial Insemination Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Artificial Insemination Market, by as technique type:

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal
• Others

Artificial Insemination Market, by component type:

• Insemination Kits
• Home Conception Devices
• Others

Artificial Insemination Market, by source type:

• AIH-Husband
• AID-Donor

Artificial Insemination Market, by end user type:

• Hospitals
• Fertility Clinics & Centers
• Others

Medical market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Europe & CIS
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Artificial Insemination Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Artificial Insemination Market

5. Voice of Customer

6. Global Artificial Insemination Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique (Intrauterine, Intracervical, Intravaginal, Intratubal)
  • 6.2.2. By Component (Insemination Kits, Home Conception Devices, Others)
  • 6.2.3. By Source (AIH-Husband v/s AID-Donor)
  • 6.2.4. By End User (Hospitals, Fertility Clinics & Centers, Others)
  • 6.2.5. By Company (2021)
  • 6.2.6. By Region
• 6.3. Product Market Map

7. North America Artificial Insemination Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By Component
  • 7.2.3. By Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Artificial Insemination Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By Component
      • 7.3.1.2.3. By Source
      • 7.3.1.2.4. By End User
  • 7.3.2. Mexico Artificial Insemination Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By Component
      • 7.3.2.2.3. By Source
      • 7.3.2.2.4. By End User
  • 7.3.3. Canada Artificial Insemination Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By Component
      • 7.3.3.2.3. By Source
      • 7.3.3.2.4. By End User

8. Europe Artificial Insemination Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By Component
  • 8.2.3. By Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Artificial Insemination Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By Component
      • 8.3.1.2.3. By Source
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Artificial Insemination Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By Component
      • 8.3.2.2.3. By Source
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Artificial Insemination Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By Component
      • 8.3.3.2.3. By Source
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Artificial Insemination Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technique
      • 8.3.4.2.2. By Component
      • 8.3.4.2.3. By Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Artificial Insemination Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technique
      • 8.3.5.2.2. By Component
      • 8.3.5.2.3. By Source
      • 8.3.5.2.4. By End User

9. Asia-Pacific Artificial Insemination Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By Component
  • 9.2.3. By Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Artificial Insemination Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By Component
      • 9.3.1.2.3. By Source
      • 9.3.1.2.4. By End User
  • 9.3.2. India Artificial Insemination Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By Component
      • 9.3.2.2.3. By Source
      • 9.3.2.2.4. By End User
  • 9.3.3. South Korea Artificial Insemination Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By Component
      • 9.3.3.2.3. By Source
      • 9.3.3.2.4. By End User
  • 9.3.4. Japan Artificial Insemination Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Technique
      • 9.3.4.2.2. By Component
      • 9.3.4.2.3. By Source
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Artificial Insemination Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Technique
      • 9.3.5.2.2. By Component
      • 9.3.5.2.3. By Source
      • 9.3.5.2.4. By End User

10. South America Artificial Insemination Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By Component
  • 10.2.3. By Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Insemination Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By Component
      • 10.3.1.2.3. By Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Artificial Insemination Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By Component
      • 10.3.2.2.3. By Source
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Artificial Insemination Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By Component
      • 10.3.3.2.3. By Source
      • 10.3.3.2.4. By End User

11. Middle East and Africa Artificial Insemination Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Technique
  • 11.2.2. By Component
  • 11.2.3. By Source
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Artificial Insemination Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Technique
      • 11.3.1.2.2. By Component
      • 11.3.1.2.3. By Source
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Artificial Insemination Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Technique
      • 11.3.2.2.2. By Component
      • 11.3.2.2.3. By Source
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Artificial Insemination Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Technique
      • 11.3.3.2.2. By Component
      • 11.3.3.2.3. By Source
      • 11.3.3.2.4. By End User
  • 11.3.4. Egypt Artificial Insemination Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Technique
      • 11.3.4.2.2. By Component
      • 11.3.4.2.3. By Source
      • 11.3.4.2.4. By End User
  • 11.3.5. Turkey Artificial Insemination Market Outlook
    • 11.3.5.1. Market Size & Forecast
      • 11.3.5.1.1. By Value
    • 11.3.5.2. Market Share & Forecast
      • 11.3.5.2.1. By Technique
      • 11.3.5.2.2. By Component
      • 11.3.5.2.3. By Source
      • 11.3.5.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

• 14.1. Rocket Medical plc
• 14.2. Kitazato Corporation
• 14.3. Vitrolife AB
• 14.4. Genea Limited
• 14.5. Rinovum Women's Health, LLC
• 14.6. Pride Angel Limited
• 14.7. FUJIFILM Irvine Scientific, Inc.
• 14.8. Conceivex, Inc.
• 14.9. Surelife Pte Ltd.
• 14.10. Biogenics Inc.

15. Strategic Recommendations